TY - JOUR
T1 - Multi-omic profiles of neuroendocrine neoplasms of the pancreas
T2 - an integrated landscape
AU - Bevere, Michele
AU - Gkountakos, Anastasios
AU - Valentinuzzi, Silvia
AU - De Fabritiis, Simone
AU - Wong, Chee S
AU - De Robertis, Riccardo
AU - Mattiolo, Paola
AU - Gentiluomo, Manuel
AU - Fassan, Matteo
AU - Pea, Antonio
AU - Crinò, Stefano F
AU - Simbolo, Michele
AU - Mafficini, Andrea
AU - Campa, Daniele
AU - Cingarlini, Sara
AU - Landoni, Luca
AU - Lawlor, Rita T
AU - Salvia, Roberto
AU - D'Onofrio, Mirko
AU - Milella, Michele
AU - Adsay, Volkan
AU - Brosens, Lodewijk A
AU - Heaphy, Christopher M
AU - Hong, Seung-Mo
AU - Singhi, Aatur D
AU - Scarpa, Aldo
AU - Luchini, Claudio
N1 - Publisher Copyright:
© The Author(s) 2026.
PY - 2026/7/31
Y1 - 2026/7/31
N2 - Pancreatic neuroendocrine neoplasms (PanNENs) constitute a heterogeneous group of tumors distinguished by substantial variability in morphology, immunophenotype, molecular characteristics, and clinical behavior. In recent years, the advent of multiple omics-based methodologies has significantly enhanced our understanding of these neoplasms. Integrating histology and genomics with survival analyses has clarified that the fundamental distinction within this disease spectrum lies between well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Furthermore, genomics, transcriptomics, and epigenetic profiling have deepened the granularity of the PanNET landscape, revealing marked differences even within the same diagnostic category, with important clinical implications. For example, DAXX/ATRX mutations, activation of the alternative lengthening of telomeres pathway, BEND2 gene fusions, and an α-cell transcriptional profile are more frequently associated with adverse outcomes. Additional omics approaches, including metabolomics, proteomics, radiomics, and the more recently developed spatially resolved methodologies, are further expanding current knowledge in this challenging field. In this review, we provide an integrated overview of PanNENs, synthesizing insights generated across diverse multi-omics platforms.
AB - Pancreatic neuroendocrine neoplasms (PanNENs) constitute a heterogeneous group of tumors distinguished by substantial variability in morphology, immunophenotype, molecular characteristics, and clinical behavior. In recent years, the advent of multiple omics-based methodologies has significantly enhanced our understanding of these neoplasms. Integrating histology and genomics with survival analyses has clarified that the fundamental distinction within this disease spectrum lies between well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Furthermore, genomics, transcriptomics, and epigenetic profiling have deepened the granularity of the PanNET landscape, revealing marked differences even within the same diagnostic category, with important clinical implications. For example, DAXX/ATRX mutations, activation of the alternative lengthening of telomeres pathway, BEND2 gene fusions, and an α-cell transcriptional profile are more frequently associated with adverse outcomes. Additional omics approaches, including metabolomics, proteomics, radiomics, and the more recently developed spatially resolved methodologies, are further expanding current knowledge in this challenging field. In this review, we provide an integrated overview of PanNENs, synthesizing insights generated across diverse multi-omics platforms.
U2 - 10.1186/s12943-026-02697-4
DO - 10.1186/s12943-026-02697-4
M3 - Review article
C2 - 42210310
SN - 1476-4598
VL - 25
JO - Molecular Cancer
JF - Molecular Cancer
IS - 1
M1 - 186
ER -